DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ℹ️ Observational Association Only Evidence
A comparative study in adults with type 2 diabetes found GLP-1 receptor agonists were associated with increased risk for nonscarring alopecia versus both SGLT-2 and DPP-4 inhibitors. The reported association persisted across sensitivity analyses, although absolute event rates were low.
Clinical Considerations
- GLP-1 receptor agonists were associated with higher alopecia risk versus SGLT-2 inhibitors (HR 1.37).
- Risk was also higher versus DPP-4 inhibitors (HR 1.68) in adjusted analyses.
- The signal appeared specific to nonscarring alopecia rather than broader hair-loss diagnoses.
- Findings represent associational evidence and do not establish a direct causal relationship.
Practice Applications
- Recognize hair-loss concerns as a potential discussion point during GLP-1 treatment.
- Interpret observed risk estimates within the context of low absolute risk.
- Monitor patient-reported changes in hair density during follow-up visits.
- Avoid assuming causality from comparative observational data alone.
